{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:28:27Z","timestamp":1782602907009,"version":"3.54.5"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1053\/j.seminhematol.2013.11.008","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T10:18:31Z","timestamp":1384424311000},"page":"52-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Angioimmunoblastic T-Cell Lymphoma Management"],"prefix":"10.1053","volume":"51","author":[{"given":"Kailash","family":"Mosalpuria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.Gregory","family":"Bociek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2013.11.008_bib1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project","volume":"13","author":"Rudiger","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib2","series-title":"International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2013.11.008_bib4","first-page":"627","article-title":"Angioimmunoblastic lymphadenopathy with dysproteinemia","volume":"20","author":"Freter","year":"1993","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2013.11.008_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0002-9343(75)90466-0","article-title":"Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course","volume":"59","author":"Frizzera","year":"1975","journal-title":"Am J Med"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib6","doi-asserted-by":"crossref","unstructured":"de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol. 2010;148:673-89","DOI":"10.1111\/j.1365-2141.2009.08003.x"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib7","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1309\/AJCPQXKCHQH4VAJ5","article-title":"Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement","volume":"131","author":"Cho","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archderm.136.7.881","article-title":"Cutaneous involvement in patients with angioimmunoblastic lymphadenopathy with dysproteinemia: a clinical, immunohistological, and molecular analysis","volume":"136","author":"Martel","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib9","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the International Peripheral T-Cell Lymphoma Project","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/10428199909058412","article-title":"Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature","volume":"32","author":"Pautier","year":"1999","journal-title":"Leukemia Lymph"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.critrevonc.2008.06.012","article-title":"Angioimmunoblastic T-cell lymphoma","volume":"68","author":"Iannitto","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V99.2.627","article-title":"Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10","volume":"99","author":"Attygalle","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00000478-198904000-00002","article-title":"Angioimmunoblastic lymphadenopathy\u2013type of T-cell lymphoma with a high content of epithelioid cells. Histopathology and comparison with lymphoepithelioid cell lymphoma","volume":"13","author":"Patsouris","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib15","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/jcp.40.9.995","article-title":"Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification","volume":"40","author":"Suchi","year":"1987","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00428-004-1114-1","article-title":"In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study","volume":"446","author":"Willenbrock","year":"2005","journal-title":"Virchows Arch Int J Pathol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib17","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood-2004-03-1206","article-title":"Unique gene expression program of human germinal center T helper cells","volume":"104","author":"Kim","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib18","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/01.MP.0000084630.64243.D1","article-title":"Benign CD10-positive T cells in reactive lymphoid proliferations and B-cell lymphomas","volume":"16","author":"Cook","year":"2003","journal-title":"Mod Pathol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib19","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000478-200604000-00009","article-title":"Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells","volume":"30","author":"Dupuis","year":"2006","journal-title":"AmJ Surg Pathol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib20","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2005-03-1083","article-title":"Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?","volume":"106","author":"Grogg","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib21","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1309\/MC7QRGPTV0LRR98X","article-title":"The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas","volume":"128","author":"Stacchini","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nri1714","article-title":"Follicular B helper T cells in antibody responses and autoimmunity","volume":"5","author":"Vinuesa","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib23","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma","volume":"30","author":"Dorfman","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib24","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood-2006-01-0394","article-title":"Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells","volume":"108","author":"Krenacs","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3324\/haematol.10864","article-title":"Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma","volume":"92","author":"Roncador","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib26","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.humpath.2007.11.012","article-title":"Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia","volume":"39","author":"Xerri","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1309\/AJCP62WRKERPXDRT","article-title":"Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma","volume":"131","author":"Yu","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0165-4608(90)90200-T","article-title":"Inv(14)(q11q32) in one of four different clones in a case of angioimmunoblastic lymphadenopathy","volume":"44","author":"Schlegelberger","year":"1990","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib29","first-page":"179","article-title":"Angioimmunoblastic lymphadenopathy with trisomy 3: the cells of the malignant clone are T cells","volume":"4","author":"Schlegelberger","year":"1990","journal-title":"Hem Pathol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1996.14.2.593","article-title":"Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type","volume":"14","author":"Schlegelberger","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib31","doi-asserted-by":"crossref","unstructured":"Willenbrock K, Roers A, Seidl C, Wacker HH, Kuppers R, Hansmann ML. Analysis of T-cell subpopulations in T-cell non-Hodgkin's lymphoma of angioimmunoblastic lymphadenopathy with dysproteinemia type by single target gene amplification of T cell receptor- beta gene rearrangements. AmJ Pathol. 2001;158:1851-7.","DOI":"10.1016\/S0002-9440(10)64141-7"},{"issue":"7","key":"10.1053\/j.seminhematol.2013.11.008_bib32","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V79.7.1789.1789","article-title":"Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma","volume":"79","author":"Weiss","year":"1992","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2141.2007.06620.x","article-title":"Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load","volume":"138","author":"Zhou","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib34","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib35","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib36","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.1158\/0008-5472.CAN-07-1708","article-title":"Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation","volume":"67","author":"Piccaluga","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/MOH.0b013e328186ffbf","article-title":"Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications","volume":"14","author":"Dunleavy","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine","volume":"48","author":"Advani","year":"2007","journal-title":"Leukemia Lymph"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib39","article-title":"Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone","volume":"91","author":"Ramasamy","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib40","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma : results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib41","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"S1","key":"10.1053\/j.seminhematol.2013.11.008_bib42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/hon.2057","article-title":"Oral presentations","volume":"31","author":"Horowitz","year":"2013","journal-title":"Hematol Oncology"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib43","first-page":"1594","article-title":"Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma","volume":"97","author":"Larue","year":"2011","journal-title":"A clinicobiological study of the GELA. Haematologica"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib44","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib45","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2013.11.008_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib47","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/sj.leu.2403936","article-title":"Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab","volume":"19","author":"Bruns","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib48","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/annonc\/mdm579","article-title":"Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab","volume":"19","author":"Aguiar Bujanda","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib49","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/ijc.25873","article-title":"Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection","volume":"129","author":"Iwata","year":"2011","journal-title":"Int J Cancer J Int Cancer"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib50","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib51","doi-asserted-by":"crossref","unstructured":"Delmer A, Fitoussi O, Gaulard P, Laurent G, Bordessoule D, Morschhauser F, et al, editors. A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial. J Clinl Oncol. 2009;27(15).","DOI":"10.1200\/jco.2009.27.15_suppl.8554"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib52","doi-asserted-by":"crossref","first-page":"9945","DOI":"10.1158\/0008-5472.CAN-07-1148","article-title":"A human CD4 monoclonal antibody for the treatment of T\u2010cell lymphoma combines inhibition of T\u2010cell signaling by a dual mechanism with potent Fc\u2010dependent effector activity","volume":"67","author":"Rider","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma","volume":"150","author":"D\u2019Amore","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib54","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3816\/CLM.2000.n.009","article-title":"DAB389IL\u20102 (ONTAK): a novel fusion toxin therapy for lymphoma","volume":"1","author":"Foss","year":"2000","journal-title":"Clin Lymph"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib55","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib56","doi-asserted-by":"crossref","unstructured":"Foss, Francine M, Nelida Sjak-Shie, Andre Goy, Eric Jacobsen, Ranjana Advani, et al. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leukemia & lymphoma 0. 2013;1-7.","DOI":"10.3109\/10428194.2012.742521"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib57","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome\u2014Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib58","first-page":"1272","article-title":"Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig","year":"2003","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib59","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem - cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.008_bib60","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196313001583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196313001583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:22:19Z","timestamp":1758522139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196313001583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0037196313001583"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2013.11.008","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angioimmunoblastic T-Cell Lymphoma Management","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2013.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}